A Phase 4 interventional study of placebo and varenicline in Smoking Cessation, sponsored by Pfizer. Completed at 33 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-11-20.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one is the 17th largest by enrollment, is one of 14 that started in 2008, is one of 47 in phase 4, and was the 26th registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 659 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is one of 8 that started in 2008, is one of 11 in phase 4, and was the 21st registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: placebo
Drug: varenicline
placebo tablet taken orally twice daily for 12 weeks
varenicline tablets, 1 mg taken orally twice daily for 12 weeks
Also known as: Chantix, Champix
Percentage of Participants With 4-week Continuous Abstinence (CA)
The percentage of participants who reported complete abstinence from cigarette smoking and other nicotine use (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \>10 parts per million (ppm) at any visits Week 9 through Week 12. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.
Time frame: Week 9 through Week 12
Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24
Percentage of participants with CA from cigarette smoking and other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use, who did not have CO \>10 ppm at any visits Week 9 through Week 24. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.
Time frame: Week 9 through Week 24
Percentage of Participants With Long Term Quit Through Week 24
Responder for the primary endpoint of CA from Week 9 through Week 12 and who had no more than 6 days of smoking during the non-treatment phase of the study. For Weeks 13, 16, 20, and 24, long term quit was determined by CO-confirmed in-clinic visit.
Time frame: Week 9 through Week 24
Percentage of Participants With 7-day Point Prevalence of Nonsmoking (Smoking Cessation)
Percentage of participants with complete abstinence from cigarette smoking or other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use for the 7 days prior to Week 12 and Week 24, respectively, who did not have CO \>10 ppm at any visits. CO-confirmed in-clinic visit.
Time frame: Week 12 and Week 24
Percentage of Participants With 4-week Point Prevalence of Nonsmoking
Percentage of participants with complete abstinence from cigarette smoking or use of tobacco products for the 4 weeks prior to Week 24 who did not have CO \>10 ppm at any visits.
Time frame: Week 24
Change From Baseline in Fagerström Test for Nicotine Dependence (FTND) to Day of First Quit Attempt (FQA) Through Week 5 by Smoking Status at Weeks 9-12
Change in nicotine dependence from baseline to the date of the FQA within the first 5 weeks. FTND was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The FTND contains 4 yes-no and 2 multiple choice questions and can be used in a self-report format. The items on FTND are scored 0 to 3 for multiple choice items, the items are summed to yield a total score of 0-10 (0=minimum nicotine dependence; 10=maximum nicotine dependence).
Time frame: Baseline through Week 5
| Milestone | Varenicline | Placebo |
|---|---|---|
| Started | 493 | 166 |
| Received treatment | 486 | 165 |
| Completed | 425 | 141 |
| Not completed | 68 | 25 |
| Withdrew: Adverse event | 14 | 6 |
| Withdrew: Lost to follow-up | 17 | 10 |
| Withdrew: Withdrawal by subject | 24 | 7 |
| Withdrew: Other known cause | 6 | 1 |
| Withdrew: Randomized by not treated | 7 | 1 |
The percentage of participants who reported complete abstinence from cigarette smoking and other nicotine use (on the Nicotine Use Inventory) and who did not have carbon monoxide (CO) \>10 parts per million (ppm) at any visits Week 9 through Week 12. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With 4-week Continuous Abstinence (CA) | 53.9 | 19.4 |
Percentage of participants with CA from cigarette smoking and other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use, who did not have CO \>10 ppm at any visits Week 9 through Week 24. A participant was considered a responder if they met the following criterion: said they had not smoked or used nicotine products 'since the last visit' and did not have CO \>10 ppm.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With Continuous Abstinence (CA) From Smoking Weeks 9-24 | 35.2 | 12.7 |
Responder for the primary endpoint of CA from Week 9 through Week 12 and who had no more than 6 days of smoking during the non-treatment phase of the study. For Weeks 13, 16, 20, and 24, long term quit was determined by CO-confirmed in-clinic visit.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With Long Term Quit Through Week 24 | 40.7 | 14.6 |
Percentage of participants with complete abstinence from cigarette smoking or other nicotine-containing (treatment phase) or tobacco (non-treatment phase) products use for the 7 days prior to Week 12 and Week 24, respectively, who did not have CO \>10 ppm at any visits. CO-confirmed in-clinic visit.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Week 12 | 59.5 | 24.2 |
| Week 24 | 43.0 | 17.6 |
Percentage of participants with complete abstinence from cigarette smoking or use of tobacco products for the 4 weeks prior to Week 24 who did not have CO \>10 ppm at any visits.
| Percentage of participants | Varenicline | Placebo |
|---|---|---|
| Percentage of Participants With 4-week Point Prevalence of Nonsmoking | 42.0 | 17.0 |
Change in nicotine dependence from baseline to the date of the FQA within the first 5 weeks. FTND was designed to provide an ordinal measure of nicotine dependence related to cigarette smoking. It contains items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. The FTND contains 4 yes-no and 2 multiple choice questions and can be used in a self-report format. The items on FTND are scored 0 to 3 for multiple choice items, the items are summed to yield a total score of 0-10 (0=minimum nicotine dependence; 10=maximum nicotine dependence).
| Units on a scale | Varenicline | Placebo |
|---|---|---|
| Responders | -2.3 ± 2.53 | -1.8 ± 1.95 |
| Non-Responders | -2.5 ± 2.55 | -1.8 ± 2.13 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline | — | 6/486 (1.2%) | 297/486 (61.1%) |
| Placebo | — | 1/165 (0.6%) | 79/165 (47.9%) |
| Event | Varenicline | Placebo |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/486 | 1/165 |
| Intervertebral disc protrustionMusculoskeletal and connective tissue disorders | 2/486 | 0/165 |
| Carotid artery stenosisNervous system disorders | 1/486 | 0/165 |
| SyncopeNervous system disorders | 1/486 | 0/165 |
| Calculus uretericRenal and urinary disorders | 1/486 | 0/165 |
| PyelocaliectasisRenal and urinary disorders | 1/486 | 0/165 |
| Ureteric obstructionRenal and urinary disorders | 1/486 | 0/165 |
| Peripheral arterial occlusive diseaseVascular disorders | 1/486 | 0/165 |
| Event | Varenicline | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 142/486 | 15/165 |
| Abnormal dreamsPsychiatric disorders | 61/486 | 5/165 |
| HeadacheNervous system disorders | 55/486 | 20/165 |
| InsomniaPsychiatric disorders | 43/486 | 6/165 |
| NasopharyngitisInfections and infestations | 34/486 | 14/165 |
| DizzinessNervous system disorders | 8/486 | 8/165 |
| ConstipationGastrointestinal disorders | 23/486 | 5/165 |
| FatigueGeneral disorders | 23/486 | 3/165 |
| Sleep disorderPsychiatric disorders | 20/486 | 6/165 |
| VomitingGastrointestinal disorders | 19/486 | 1/165 |
| Age, Customized(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Between 18 and 44 years | 248 | 93 | 341 |
| Between 45 and 64 years | 209 | 64 | 273 |
| >= 65 years | 29 | 8 | 37 |
| Sex: Female, Male(Participants) | Varenicline | Placebo | Total |
|---|---|---|---|
| Female | 193 | 66 | 259 |
| Male | 293 | 99 | 392 |
The record gives a start of Sep 2008, a primary completion of Sep 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline